Customs Classification of Implantable Liquid Embolic Agents: CAAR Delhi Ruling on Onyx System
The classification of advanced medical devices under the Customs Tariff Act often presents complex challenges, particularly when the product in question bridges the gap between chemical substances and mechanical implants. A recent advance ruling by the Customs Authority for Advance Rulings (CAAR), New Delhi, in the case of In re India Medtronic Private Limited, has provided significant clarity regarding the classification of liquid embolic systems.
This detailed analysis explores the intricacies of the ruling, the technical nature of the product, the competing legal interpretations, and the final verdict that places such devices under the category of artificial parts of the body.
Background of the Application
The applicant, India Medtronic Private Limited, a prominent entity engaged in the distribution of medical technologies, approached the CAAR seeking certainty regarding the classification of their imported product, the "Onyx Embolization Liquid System." The application was submitted under the provisions of Section 28H(2) of the Customs Act, 1962, read alongside the CAAR Regulations, 2021.
The core objective of the application was to determine whether the product should be classified as a general medical appliance or specifically as an artificial part of the body, a distinction that holds weight in terms of regulatory compliance and tariff interpretation.
Technical Specifications of the Product
To understand the legal classification, one must first comprehend the technical nature of the goods. The Onyx Embolization Liquid System is a specialized medical device utilized primarily in neurovascular and peripheral vascular interventions.
Composition and Mechanism
The product is a non-adhesive liquid embolic agent comprising three critical components:
- Ethylene Vinyl Alcohol (EVOH) Copolymer: This serves as the structural material or the "blocker."
- Dimethyl Sulfoxide (DMSO): This acts as a solvent carrier, maintaining the EVOH in a liquid state prior to injection.
- Micronized Tantalum Powder: This provides radiopacity, allowing the surgeon to visualize the liquid under fluoroscopy during the procedure.
Mode of Action
The system is introduced into the body via a microcatheter. The mechanism of action is purely physical and mechanical rather than pharmacological. When the mixture is injected into the target site and comes into contact with blood, the DMSO solvent diffuses away. This causes the EVOH copolymer to precipitate and solidify in situ.
The result is the formation of a spongy, coherent polymer cast. This cast permanently occludes abnormal blood vessels. The product is indicated for treating conditions such as:
- Cerebral Arteriovenous Malformations (AVMs)
- Dural Arteriovenous Fistulas (DAVFs)
- Hypervascular tumors
- Aneurysms and other vascular hemorrhages